Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic) (2019 - 2026)

InMed Pharmaceuticals has reported EPS (Basic) over the past 5 years, most recently at -$0.51 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 85.99% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$3.32, up 75.57%, while the annual FY2025 figure was -$8.36, 58.49% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.51 at InMed Pharmaceuticals, down from -$0.44 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.28 in Q2 2023 and troughed at -$15.24 in Q3 2023.
  • A 5-year average of -$4.12 and a median of -$3.61 in 2024 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): surged 102.15% in 2023 and later tumbled 1407.14% in 2024.
  • Year by year, EPS (Basic) stood at -$7.73 in 2021, then skyrocketed by 88.23% to -$0.91 in 2022, then tumbled by 307.69% to -$3.71 in 2023, then rose by 1.89% to -$3.64 in 2024, then skyrocketed by 85.99% to -$0.51 in 2025.
  • Business Quant data shows EPS (Basic) for INM at -$0.51 in Q4 2025, -$0.44 in Q3 2025, and -$0.43 in Q2 2025.